2024-11-0920220006-497110.1182/blood-2022-165385http://dx.doi.org/10.1182/blood-2022-165385https://hdl.handle.net/20.500.14288/11459N/AHematologyGlofitamab in relapsed/refractory Diffuse Large B Cell Lymphoma: real world dataMeeting Abstract1528-0020893223206319Q111962